Bailitiheng: The first administration of the injectable BL-M14D1 in combination with immunotherapy for first-line SCLC in a global Phase III clinical trial has been completed.

Baillie Tianheng announced that the company's self-developed innovative biopharmaceutical BL-M14D1 combined with PD-L1 monoclonal antibody has recently completed its first subject dosing in a global multi-center Phase III clinical trial for first-line treatment of extensive-stage small cell lung cancer, compared to platinum-based chemotherapy combined with PD-L1 monoclonal antibody. This study is the world's first Phase III clinical research on ADC + immunotherapy for first-line extensive-stage small cell lung cancer.